Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated efficacy in improving NAFLD, while their effectiveness on liver fibrosis is limited in type 2 diabetic patients. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.